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Mammalian Target of Rapamycin (mTOR) is a serine/
threonine protein kinase that acts as a master switch
between anabolic and catabolic functions of the human
body in pathways stimulated by insulin, growth factors
and mitogen [1]. mTOR functions as a central controller
of growth, proliferation, metabolism and angiogenesis,
but its signaling is dysregulated in various human dis-
eases especially certain cancers like renal cell carcinoma
and breast cancer [2]. In cancer, mTOR is frequently
hyperactivated which promotes cancer development and
progression. In certain cancers, resistance to antineo-
plastic agents such as topoisomerase 1, topoisomerase 2
inhibitors and methotrexate can be overcome with a
synergistic combination with mTOR inhibitors [3,4].
Furthermore, mTOR activates the degradation of cyclin
dependent kinases such as CDK1 which increases synth-
esis of dihydrofolate reductases. By decreasing this
enzyme, mTOR inhibitors like sirolimus and temsiroli-
mus, promote tumour sensitivity to agents such as
methotrexate [4].
Recent development has made cancer treatment move
on from conventional cytotoxic drugs to agents that tar-
get specific proteins like mTOR called mTOR inhibitors.
A very common mTOR inhibitor, rapamycin, is a bacter-
ial product that inhibits mTOR by associating with its
intracellular receptor [5]. [Currently, two mTOR inhibi-
tors, temsirolimus and everolimuswhich are derivatives
of rapamycin, temsirolimus(Torisel: Wyeth-Ayerst, Char-
lotte, NC, U.S.A.) and everolimus(Certican: Novartis
Pharmaceuticals, St. Louis, MO, U.S.A.) ] are approved
for the treatment of patients with advanced renal cell car-
cinoma (RCC) and mantle cell lymphoma, effectively
translating this paradigm into the clinical setting [6].
mTOR inhibitors (like other drugs) have an adverse
effect profile. Clinical trials have had mixed opinions
regarding drug efficacy [7]. Examples of the neoplasias
with promising results include pancreatic
neuroendocrine tumors, follicular lymphoma, renal cell
carcinoma and mantle cell lymphoma while the ones
with negative results include glioblastoma multiforme
and small cell carcinoma of lung. Although relatively
safe, these drugs are associated with some unique
adverse side effects, such as hyperlipidemia, hyperglyce-
mia, and pneumonitis, which require monitoring and
may require clinical intervention [6]. Clinical utility of
mTOR inhibitors depends on appropriate selection of
patients and type of cancer. Mutations in the mTOR
pathway of cancer cells may result in resistance to
mTOR inhibition and prevent any action of the mTOR
inhibitors. Examples include mutations of FKBP-12 pro-
teins, mammalian 14-3-3 proteins ATM (ataxia telan-
giectasia, mutated) cells, all responsible for growth of
cancer cells.
A new wave of clinical trials has commenced using a
second generation of mTORC1 and mTORC2 inhibitors.
First generation of mTOR inhibitors like rapamycin,
showed certain limitations by blocking only C1 isoform,
inducing feedback activation of Akt and showing resis-
tance to mTORC2 [8]. The newer agents can inhibit
both mTORC1 and mTORC2 by targeting kinase
domains as an effective means with a high degree of
selectivity [9]. For example, Agent OSI-027 (OSI Phar-
maceuticals, Melville, NY, U.S.A.) is currently in phase 1
of trial and being evaluated on patients with lymphoma
or solid tumors [9]. XL765 (Exelixis, San Francisco, CA,
U.S.A.) is also in phase 1 of clinical trial and being
assessed in combination therapies [9].
In contrast to the older mTOR inhibitors like rapamy-
cin which blocked only C1 isoform, the newer agents can
inhibit both mTORC1 and 2 with high degree of selectiv-
ity [10]. Further clinical trials are necessitated to deter-
mine the therapeutic uses, predictive biomarkers and
clinical efficacy for this novel class of anti-cancer agents.
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